Blinatumomab and low-dose DLI after transplant for B-ALL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests adding a drug called blinatumomab plus a low-dose donor lymphocyte infusion (DLI) as maintenance therapy after stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL). It aims to reduce the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be under 70 years old.
- You must have a diagnosis of high-risk B-ALL and be in remission (MRD-negative) after a stem cell transplant.
- Your liver and kidney function must be within certain limits.
- You must not have active graft-versus-host disease (GVHD) or uncontrolled infections.
- You must not be pregnant or breastfeeding.
- You must have no severe allergies to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
This trial tests a drug called blinatumomab for people with B-ALL whose leukemia has come back at a very low level (detected only by sensitive testing) after a stem cell transplant. The goal is to see if blinatumomab can clear these remaining leukemia cells and prevent a full relapse.
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
This trial tests if a targeted drug, blinatumomab, can help prevent leukemia from coming back after a stem cell transplant. It is for people with high-risk B-cell acute lymphoblastic leukemia who have achieved remission but are at high risk of relapse.
This study tests if blinatumomab, an immunotherapy drug, can prevent B-cell acute lymphoblastic leukemia (B-ALL) from coming back in people who have already had a donor stem cell transplant. You may qualify if you had a relapse before transplant or had a positive minimal residual disease test, and if you are now in complete remission after the transplant.
This trial tests giving a drug called blinatumomab before a stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) that is in remission and has no detectable cancer cells. The goal is to see if this extra treatment helps prevent the leukemia from coming back after transplant.
Hear when a new ALL (Acute B-Lymphoblastic Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.